GlassScriptPhysician profile
Sara Nunnery
NPI 1922462555
$35,555.46
in general payments reported to CMS, 2019-2025
25 companies · $30K in 2025
The $30K reported for 2025 was more than what 92% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $5,291 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $4,136 · Food and Beverage: $3,097 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,972.50 |
| Travel and Lodging | $4,136.22 |
| Food and Beverage | $3,096.74 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10,306.05 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Stemline Therapeutics INC. | $8,217.16 | 2024-2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $6,772.56 | 2024-2025 | Datroway, Tagrisso, Calquence |
| Gilead Sciences, INC. | $4,660.09 | 2024-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $1,938.17 | 2024-2025 | |
| Daiichi Sankyo INC. | $1,672.53 | 2024-2025 | Enhertu, Injectafer |
| Eli Lilly and Company | $1,250.00 | 2025 | Verzenio |
| Kite Pharma, INC. | $146.82 | 2025 | Yescarta |
| Astellas Pharma US INC | $115.35 | 2024-2025 | Vyloy |
| Pfizer INC. | $74.90 | 2025 | |
| Incyte Corporation | $46.20 | 2024 | Jakafi, Pemazyre, Monjuvi |
| Janssen Biotech, INC. | $44.99 | 2024 | Rybrevant, Talvey, Tecvayli |
| Aveo Pharmaceuticals, INC. | $40.76 | 2024 | |
| Puma Biotechnology, INC. | $39.59 | 2025 | |
| Legend Biotech USA INC. | $31.91 | 2025 | Carvykti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $29.65 | 2024 | Poteligeo |
| Celgene Corporation | $25.35 | 2025 | Reblozyl |
| Genmab U.S., INC. | $25.26 | 2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $25.10 | 2025 | |
| Mirati Therapeutics, INC. | $21.89 | 2024 | Krazati |
| Syndax Pharmaceuticals, INC. | $20.01 | 2025 | |
| Beigene USA, INC. | $17.14 | 2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $17.11 | 2024 | Cosela |
| Fennec Pharmaceuticals, INC. | $16.87 | 2025 | Fyarro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Nunnery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.